ArticleDiscover nano2026
Size dependent antibacterial mechanism of magnesium oxide nanoparticles against Ralstonia solanacearum.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Magnesium oxide nanoparticles (MgONPs) demonstrate size-influenced antibacterial activity against Ralstonia solanacearum, with physical disruption mechanisms appearing to play a more prominent role than reactive oxygen species (ROS) effects under the tested conditions. While 30 nm particles generated maximum ROS levels, 20 nm MgONPs exhibited superior bactericidal efficacy, reducing survival to 36% at 300 mg/L versus 46% for 30 nm particles-a superiority consistently supported by motility, membrane, and transcriptomic assessments even at the complete-killing concentration (500 mg/L). This size-dependent efficacy was further validated in vivo. ROS scavenging tests and transcriptomics suggested that oxidative stress may not be the primary driver of antimicrobial action, though a potential synergistic role cannot be entirely excluded. The primary mechanisms involved size-specific physical membrane damage, DNA integrity changes, and metabolic interference. Smaller particles (20 nm) caused significant membrane destabilization and uniquely disrupted acetyl-CoA metabolism and oxidoreductase activity through downregulation of ribosome biogenesis, oxidative phosphorylation, and amino acid degradation pathways. Transcriptomic profiling revealed that particle size modulates catabolic gene expression and redox-related processes, with 20 nm particles inducing distinct metabolic suppression patterns. This study provides insights into the ongoing debate regarding ROS versus physical mechanisms, suggesting that nanoscale precision combined with surface properties governs antibacterial efficiency. The findings position MgONPs as a tunable antimicrobial platform where optimized particle dimensions and formulation strategies enhance pathogen control through targeted physical disruption and metabolic interference. These mechanistic insights offer a basis for engineering nanomaterials with improved bactericidal performance via optimization of multiple physicochemical properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.